Oncology

15 Dec 2017

2271
(471 votes)

Rigvir® in Romania: Your Two-Step Guide to Learn If You Qualify For Virotherapy

Don’t get desperate if one day you discover that conventional medicine is helpless in your cancer case. Truth be told, neither chemo nor radio can guarantee the results. Even though this also relates to Rigvir®, the drug is much less harmful for your healthy cells focusing only on your tumor. So, let’s find out how you can get access to virotherapy in Romania.

First Clinical Trials In 1968 and Official Registration In 4 Countries Afterwards

A few words about Rigvir® before we proceed.

Rigvir® operating principle is quite simple and clear. Rigvir® is injected intramuscularly and immediately starts to troubleshoot malignant cells. The functional mode of the vaccine lies in reaching the malignant cells to eliminate them from the inside. While doing so, not healthy tissues around the malignancy are touched.

Watch the video to find out how Rigvir® works:

As the drug itself was invented in the middle of the previous century, the very first clinical trials took place in 1968. Back then, 415 melanoma patients received the treatment, and the results showed that their level of health improved [1]. Moreover, there’s clinic experience in treating other types of cancer with Rigvir®. Therefore, each case should be studied individually.

It took almost 50 years to register Rigvir® in 2004 in Latvia. Georgia did the same in 2015 while Armenia, the neighboring country, registered the drug in 2016. The latest country to recognize Rigvir® on official level is Uzbekistan.

Although Rigvir® Was Originally Used To Fight Melanoma, Off-Label Use Showed It Can Fight A Range Of Cancer Types

The trials that have been conducted since 1968 showed the following:

  • 46–58% is the 3-year survival rate for melanoma patients treated only with surgery, while patients that were also treated with Rigvir® had a 3-year survival rate of 57-84% and a 5-year survival rate of 44–66%

  • 90% and 70% are the 3- and 5-year survival rate for ocular melanoma patients respectively

  • The 5-year survival rate for stage III stomach cancer patients after surgery was 24–33%, compared to 47–60% for those who received treatment with Rigvir®

  • The 5-year survival rate for stage II-IV rectal cancer patients after surgery was 41–68%, compared with 71–78% for those who received treatment with Rigvir®

A full list of Rigvir®-sensitive types of cancer includes:

  • Melanoma

  • Lung cancer

  • Various types of sarcoma

  • Neuroendocrine tumors

  • Glioblastoma

  • Ovarian cancer

  • Uterine cancer

  • Breast cancer

  • Bladder cancer

  • Prostate cancer

  • Kidney cancer

  • Pancreatic cancer

  • Colorectal cancer

Seeing your diagnosis on the list above means you can qualify for Rigvir® treatment, because it can possibly help you. Learn how in the next paragraph.

Virotherapy In Romania Isn’t That Common Yet, Making Rigvir® Search A Tough Task. Learn How To Qualify For Treatment In Germany.

 The list of countries that approve Rigvir® for treatment in their local clinics is expanding yearly, but unfortunately, it’s not a rapid process. That’s why find Rigvir® on Romanian territory is quite challenging.

Nevertheless, there’s a clinic in Germany that majors in virotherapy and isn’t open only for local citizens. It welcomes patients from all over the world since its establishment in 2000. Since then, more than 3,000 cancer patients got:

  • Rigvir® injections by well-qualified doctors who speak English

  • Combination of virotherapy and other medical options: acupuncture, Buserelin therapy, minimally-invasive surgery, detox etc.

  • 24/7 support and care by personnel who understands that struggling cancer takes a lot of courage and energy, so they’re always happy to help you.

  • Picturesque views on the surrounding forests, and having a rest from the rush of the outer world.

Naturally, it has become one of the world’s most visited destinations for virotherapy for cancer patients.

If you want to find out more about the clinic, click the button below. We’ll answer any questions within 24 hours. Make sure you’ve indicated your contact data right.

Every case is individual. And sometimes observing your diagnosis on the list of cancers that are vulnerable to some kind of treatment isn’t a synonym for having potentially successful treatment. Therefore, to find out whether you can really benefit from Rigvir® in the German clinic, you need to pass a free case evaluation.

To do so, please, collect the mentioned files in digital format (pdf/docx/jpg), upload them via WeTransfer service and send us the link via the button below:

  • Biopsy (or pathology) report

  • Cytology report CBC (complete blood count) + WBC (white blood cells) not older than 2 weeks

  • Blood biochemistry incl. ALT (alanine aminotransferase), creatinine, etc.

  • Radiology reports (actual images are not needed)

Having reports in English is ok as the medical experts know it very well.

As collecting the medical documentation may take a few weeks, it can be a good idea to start collecting the files as soon as possible. After submitting them, you’ll have to wait only 2–3 days to receive the answer from the cancer specialists whether you or the one you love qualify for the virotherapy course.

Virotherapy in Romania: How It Works After You Get Approved, and How Much It Costs

If you get approved for Rigvir® therapy after the free case assessment, you will receive detailed information about 7-day of treatment in Germany.

Rigvir in Romania Rigvir in Romania Rigvir in RomaniaRigvir in RomaniaRigvir in RomaniaRigvir in Romania
 
 

The one-way flight from Bucharest to Munich, Germany takes approximately 6–10 hours and starts from RON 182 if purchased three weeks beforehand. You can also choose a flight with one stop in Stuttgart. In this case, the flight takes 7,5 hours and costs 311 RON.

When you land in Munich, the clinic’s driver will meet you at the airport to take you directly to the clinic in Brannenburg. There, in addition to constant health check-ups, Rigvir® injections, daily consultations, as well as organic nutrition and cozy accommodation, you can be prescribed to have more than 1 therapy:

  • Detox — the medical team will examine how to purify your body from toxins, and you’ll be offered to have vitamins, minerals, as well as healthy food

  • Buserelin therapy works for patients with prostate and breast cancer. Buserelin is an artificial hormone that manages reproductive hormones in a patient’s body.

  • Minimally-invasive surgery was designed to facilitate recovery process: you’ll get the minimal number of cuts, and they won’t be large.

  • Acupuncture is a needle therapy, invented many centuries ago in China. The doctors there believed that humans have special flow of energy within the body, and needles can activate them to ensure a better flow. Now it have been proved that acupuncture activates the blood flow, that’s why immune powers of the organism increase.

  • Targeted radionuclide therapy is also used for treating prostate cancer patients. “Targeted” implies that, unlike radiotherapy, this one attacks only malignancies.

  • Naturopathic complex program is a range of physiotherapeutic activities to foster your immune system and health condition: magnetic field therapy, massage, lymph drainage and so on.

The 7-day treatment package in Germany costs 6,000 EUR (28,672 RON). Additional charges may arise, if you’re accompanied by a close person, who also needs meals and accommodation.

We understand that at this point you may still have a lot of questions. Please fill out the form on the right and we’ll get back to you almost immediately (but not later than within the first 24 hours).

 

 

List of References

  1. Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece, Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100.

  2. “Adapted ECHO-7 Virus RigVir Immunotherapy (oncolytic Virotherapy) Prolongs Survival in Melanoma Patients after Surgical Excision of the Tumour in a Retrospective Study.” Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurgis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina. Melanoma Research: October 2015 - Volume 25 - Issue 5 - p 421–426.

  3. Alberts, P., E. Olmane, L. Brokāne, Z. Krastiņa, M. Romanovska, K. Kupčs, S. Isajevs, G. Proboka, R. Erdmanis, J. Nazarovs, and D. Venskus, Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS, 2016. 124(10): p. 896-904.